Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of “Reduce” from Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average rating of “Reduce” by the fifteen brokerages that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $45.2727.

A number of research analysts recently issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, November 24th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,637 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $42.53, for a total transaction of $112,151.61. Following the transaction, the insider directly owned 155,856 shares of the company’s stock, valued at approximately $6,628,555.68. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Chi sold 900 shares of Hims & Hers Health stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the sale, the insider owned 291,439 shares in the company, valued at approximately $16,976,321.75. This represents a 0.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 616,431 shares of company stock valued at $32,924,482 in the last quarter. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Hims & Hers Health by 4.5% in the 3rd quarter. Vanguard Group Inc. now owns 19,518,015 shares of the company’s stock worth $1,107,062,000 after acquiring an additional 844,991 shares during the period. Capital World Investors increased its stake in shares of Hims & Hers Health by 1.2% during the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares during the period. Farallon Capital Management LLC raised its holdings in Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. State Street Corp lifted its position in Hims & Hers Health by 1.9% in the third quarter. State Street Corp now owns 7,173,214 shares of the company’s stock worth $406,865,000 after purchasing an additional 132,384 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Hims & Hers Health by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 4,746,081 shares of the company’s stock valued at $236,622,000 after purchasing an additional 71,593 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $39.79 on Monday. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health has a fifty-two week low of $23.97 and a fifty-two week high of $72.98. The firm has a 50-day simple moving average of $47.56 and a 200 day simple moving average of $50.49. The company has a market cap of $9.06 billion, a PE ratio of 73.69, a P/E/G ratio of 7.92 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s revenue was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a share repurchase program on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.